slide1
Download
Skip this Video
Download Presentation
Shahar Kol , IVF Unit Rambam Health Care Campus and Macabbi Health Services, Haifa, Israel

Loading in 2 Seconds...

play fullscreen
1 / 27

Shahar Kol , IVF Unit Rambam Health Care Campus and Macabbi Health Services, Haifa, Israel - PowerPoint PPT Presentation


  • 95 Views
  • Uploaded on

OHSS Should this be treated or be prevented ? When to cancel a cycle?  All cycles should be triggered with GnRH agonist and not by hCG!. Shahar Kol , IVF Unit Rambam Health Care Campus and Macabbi Health Services, Haifa, Israel. November, 2011. Content.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Shahar Kol , IVF Unit Rambam Health Care Campus and Macabbi Health Services, Haifa, Israel' - coy


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

OHSSShould this be treated or be prevented?When to cancel a cycle? All cycles should be triggered with GnRH agonist and not by hCG!

ShaharKol, IVF Unit Rambam Health Care Campus and Macabbi Health Services, Haifa, Israel

November, 2011

content
Content
  • How do we routinely trigger ovulation?
  • Is it in agreement with physiology?
  • Do we have other options?
  • The physiology of agonist trigger.
  • Agonist trigger main advantage: OHSS-free clinic. No need to cancel cycles, ever.
  • The advantage of agonist trigger for the “normal responder”.
how do we routinely trigger ovulation
How do we routinely trigger ovulation ?
  • We have only one option: hCG.
is it in agreement with physiology
Is it in agreement with physiology?
  • Adequate final oocyte maturation.
  • Early luteal phase over-stimulation – main reason for luteal phase defect in IVF.*
  • No FSH surge.

hCG

*Fauser and Devroey, 2003

the physiology of agonist trigger
The physiology of agonist trigger.

LH surge

Humaidan et al, 2011

the physiology of agonist trigger1
The physiology of agonist trigger.

FSH surge

Gonen et al, 1990

does it make a difference 1
Does it make a difference? (1)
  • Agonist trigger: more MII oocytes compared with hCG trigger.

Humaidan et al, 2005, 2009

Imoedemhe et al, 1991

Octay et al, 2009

does it make a difference 2
Does it make a difference? (2)

The pregnancy rate in completed cycles and the ongoing pregnancy rate per ET were

significantly higher in the study group (dual trigger) than in the control group (hCG only).

F&S 2008

Is it possible that in some patients FSH surge is needed?

does it make a difference 3
Does it make a difference? (3)

The effect of adding 450 IU of FSH to the

hCG trigger.

Lamb et al, 2011

what happens after agonist trigger
What happens after agonist trigger?

Complete luteolysis!

Induction of LH surge and oocyte maturation by GnRH analogue (Buserelin) in women undergoing ovarian stimulation for IVF

“No signs of OHSS were observed in 2 patients who on previous stimulation developed severe OHSS… GnRHa offers a new means by which OHSS can be prevented.”

Itskovitz et al, Gynecological Endocrinology 1988, 2:Suppl1, 165.

slide14

Luteal phase

Natural cycle day 7-9=

75 pg/ml vs. 18

Natural cycle day 7-9=

750 pg/ml vs. 184

Nevo et al, 2003

agonist trigger main advantage ohss free clinic no need to cancel cycles ever
Agonist trigger main advantage: OHSS-free clinic. No need to cancel cycles, ever.

“The utilization of GnRH agonist for triggering ovulation in antagonist cycles has

been a breakthrough in the elimination of OHSS.”

slide17

16 publications

Agonist: 2005 patients, not a single case of OHSS!

hCG: 92 cases in 1810 patients, 5.1%

slide18

Severe OHSS: Is it still a problem?

“In 2003-2005, 4 deaths (of the 12) were due to OHSS”.

~3 OHSS-related deaths per 100,000 ART cycles.

slide19

Three OHSS-related deaths (3:100,000 ART cycles), all had their embryos frozen.

Braat et al, 2010

hyper responder how to prevent ohss good clinical outcome
Hyper-responder: How to prevent OHSS + good clinical outcome?
  • Trigger with agonist.
  • Intensive luteal support.
slide21

OHSS high risk patients

Randomization

N=32

N=34

Dual suppression OCP’s & luprolide

HCG trigger

OCP’s + Ganirelix

luprolide trigger

LUTEAL SUPPORT:

E2 patches 0.1 mg X 3, qod

P4 in oil, 50 mg/day;

MONITOR E2+P4 LEVELS!

Engmann, et al, 2008

slide24

The advantage for the “normal responder”

Agonist

trigger

OPU

ET

antagonist

36h

4 days

FSH/hMG

1,500 IU hCG

1,500 IU hCG

slide26

”The granulosa/luteal cells obtained on the day of oocyte retrieval after agonist trigger have the capacity to respond to hCG by increasing the secretion of steroids.”

Engmann et al, 2011

ad